Harnessing CD8<sup>+</sup>CD28<sup>−</sup> Regulatory T Cells as a Tool to Treat Autoimmune Disease
T regulatory cell therapy presents a novel therapeutic strategy for patients with autoimmune diseases or who are undergoing transplantation. At present, the CD4<sup>+</sup> Treg population has been extensively characterized, as a result of defined phenotypic and functional readouts. In t...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/0c8f856cc5e947cdb4c5cf8bd03897b0 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | T regulatory cell therapy presents a novel therapeutic strategy for patients with autoimmune diseases or who are undergoing transplantation. At present, the CD4<sup>+</sup> Treg population has been extensively characterized, as a result of defined phenotypic and functional readouts. In this review article, we discuss the development and biology of CD8<sup>+</sup> Tregs and their role in murine and human disease indications. A subset of CD8<sup>+</sup> Tregs that lack the surface expression of CD28 (CD8<sup>+</sup>CD28<sup>−</sup> Treg) has proved efficacious in preclinical models. CD8<sup>+</sup>CD28<sup>−</sup> Tregs are present in healthy individuals, but their impaired functionality in disease renders them less effective in mediating immunosuppression. We primarily focus on harnessing CD8<sup>+</sup> Treg cell therapy in the clinic to support current treatment for patients with autoimmune or inflammatory conditions. |
|---|